Application status of using clopidogrel during perioperative period of percutaneous coronary intervention

Abstract

Abstract: Percutaneous coronary intervention(PCI) has become one of the most important therapeutic methods for atherosclerotic heart disease(AHD), but the following complications such a-, stent thrombosis and restenosis affected its long-term efficacy. Platelet activation was a key component of thrombosis of during perioperative period PCI. As one of the most effective anti platelet drugs, clo-pidogrel has been established its important role in preventing thrombosis during perioperative period of PCI. After several large-scale clinical trials in recent years.

Key words: clopidogrel, percutaneous coronarγ intervention, restenosis, stent thrombosis

CLC Number:

R541

WU Hui, YANG Jun, DING Jia-wang, Ll Wen-hui, Ll Song, Ll Li. Application status of using clopidogrel during perioperative period of percutaneous coronary intervention[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(12): 1354-1358.

References

[1] Smith Sc Jr, Feldman TE, Hirshfeld JW Jr, et al,ACC/AHA/SCAI 2005 Guideline Upxdate for Percutaneous Coronary Inter-vention-Summary Article: A Report of the American College olCardiology/American Heart Assciation Task Force on PracticeGuidelines (ACC/AHA/SCAI Writing Comnittee t0 Uplate the2001 Guidelines for Percutaneous Coronary Intervention)[J].Circulation, 2006;113 156-175.
[2] Mehta SR, Yusuf s, Peters RJ, et al. Efects of pretreatmentwith clopidogrel and aspirin folwed by long-term therapy in pa-tients undergoing percutaneous coronary intervention: the PCI-CURE studyl [J]. Lancet, 2001;358:527-533.
[3] Steínhubl SR, Berger PB, Mann JT, et al, Early and suslaineddual oral antiplatelet therapy follwvingpercutaneous coronary in-tervention: a randomized controlled trial[J]. JAMA, 2002;288:2411-2420.
[4] Gurhel PA, Bliden KP, Hiat BL, et al. Clopidogrel for coro-nary stenting: response variability, drug resistance, ard the ef-fect of ptetreatment platelet reactivity[J]. Cireulation, 2003;107:2908-2913.
[5] Каѕtrаtin, Меhіllі, Ѕсhоblеn H, еt аl. А сlіnісаl trіul оf аbciximab in eetive pereudaeous coronary inervenion after pre-treatment wih clopidogre[J]. N Engl J Med, 2004;350:232-238.
[6] Kastrati A, Mehilli J, Schublen H, et al. Influence of treat-ment duration with a 600mg dose of copidogrel befoe percuta-neous coronarv revascularization[J]. J Am Coll Cardio, 2004;44:2133-2136.
[7] Patti G, Colorna G, Pasceri v, et al. Randoruized trial of highloading dose of clopidogrel for reduction of periprocedural myo-cardial infarction in patienis undergoing coronary intervention;results from the ARMYDA-2 (Antiplatelet therapy for Reductionof Myocardia! Danuge during Angioplasty) study[J]. Circula-tion, 2005;111:2099-2106.
[8] Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in pr-lients with acute coronary syndmones undergoing percutancouscoronaryintervention after clopidogrel pretreatment: the ISAR-REACT₂ Randonized Trial[J]. JAMA, 2006; 295: 1581-1582.
[9] Sbatine MS, Canon CP, Gibson см, eal. Eleef clopidogrel pretratnent beforepercutancons coronary intervention inpatiens with T-levarion myx ardiad ifartion treated wilh fi-brinolytics: the PCI-CLARITY study[J]. JAMA, 200S; 294;1224-1232.
[10] Leon MB, Baim DS, PopmaJJ, et al. A clinical trial compar-ing three antithromboic-drug regimens after coronary. anerystenting. Stent Anticoagulation Restenosis Study Investigators[J]. N Engl J Med, 1998;339: 1665-1671.
[11] Moses JW, Leon MB, Popma JJ, et al.Sirolimus-eluting slentsversus standard stents in patients with stenosis in a native coro-nary artery[J]. N Engl J Med, 2003;349:1315-1323.
[12] Stone GW, Ellis SG, Cox DA, etal. A polymer-based, pacli-taxel-eluting stent in patients with coronary artery disease[J]. NEngl J Med, 2004;350:221-231.
[13] Jeremias A, Sylvia B, BridgesJ, et al. Stent thrombosis aftersuccessful srolius-eluting slent inplantation[J]. Circulation,2004; 109: 1930-1932.
[14] lakovou 1, Schmid T, Bonizoni E, et al. Incidence, predie-tors, and outcome of thưombosis after successful implantation ofdrug-eluting stents[J]. JAMA, 2005;293:2126-2130.
[15] YusufS, ZhaoF, Mehta SR.et al. Efeets of clopidogrel inaddition to aspirin in patients with acute coronary syndromeswithout ST-segment elevation[J]. N Engl J Med, 2001;345:494-502.
[16] Lemos PA, Sernys PW, van Domburg RT, et al. Unresricteduiliatio of sirlimus-cluting stents compared with convenionalbare stent implantation in the " real world": the Rapamyein-Eluing Stent Evaluated At Rotera Crdioloey Hospital (RE-SEARCH) registry[J]. Circulation, 2004; 109: 190-195.
[17] Holmes DR Jr, Leon MB, Moses JW, et al. Analysis of l-yearclinical outcomes in the SIRIUS trial: a randomized trial of asirolimus eluting stent versus a slandard stent in patients at highrisk for coronary restenosis[J]. Circulation, 2004; 109:634-640.
[18] Stone Gw, Ellis SG, Cox DA, et al. One-year clinical resultswith the slowrelease, polymer-based, paclitaxel-eluting TAXUS stent: the TA XUS-1V trial[s]. Cireulation, 2004; 109:1942-1947.
[19] MorenoR, Femandez c, Hemandez R, et al. Dng-elutingsltent thrombosis: resuls from a pooled analysis ineluding 10randomized studies[J]. J Am Coll Candio, 2005; 45: 954-959.
[20] Bavry AA Kunbhani [D], HelonTJ, etal. What is the tisk ofstent thrombosisassciated with the use of pacliaxel-elutingslends for percutaneous coronary inervenion? a meta-anlyis[J]. J Am Coll Cardio, 2005;45941-946.
[21] Esci EL, Ansron K, Kong DF, wtal. Copidogrel ueand bng-e di oucone aler dng eluing sleu implatatin[J]. JAMA, 2007;297:159-168.